Sutro Biopharma Inc
STRO
Get informed when a big investor buys or sells
+ FollowMarket Cap$245.61M
Close$
$-0.82
103.8% downside
Current Fair Value
103.8% downsideOvervalued by 103.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $245.61 Million |
|---|---|
| Enterprise Value | $208.51 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-22.49 |
| Beta | 1.52 |
| Outstanding Shares | 13,082,355 |
Return
| Return on Equity | 174.84% |
|---|---|
| Return on Assets | -92.89% |
| Return on Invested Capital | -99.21% |
Valuation & Multiples
| P/E Ratio | -1.54 |
|---|---|
| PEG | -0.65 |
| Price to Sales | 7.1 |
| Price to Book Ratio | -2.66 |
| Enterprise Value to Revenue | 4.56 |
| Enterprise Value to EBIT | -1.48 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | -0.17 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-2.19
Average shareholder expectationRevenue Estimate
$11.96 M
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-1.81
Average shareholder expectationRevenue Estimate
$12.84 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | 61,400▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 10774.37%▲ 6494.94% |
|---|---|
| Total Invested | $351.11M▲ 441.87% |
| Investors Holding | 72▲ 11.00% |
ESG Score
No data
About Sutro Biopharma Inc
CEO: William Newell